Duoforte 27 GEL
Texto original en francés.
Producto de salud natural autorizado en Canadá
- Titular
- Haleon US Holdings LLC
- NPN o DIN-HM
- 01939645
- Estado
- Licencia no activa
- Fecha de licencia
- 22 de diciembre de 2009
- Fecha de revisión
- 22 de febrero de 2017
- Forma
- Solution semblabe au collodion.
- Vía de administración
- Topique
- Tipo de solicitud
- DIN de transition
El análisis de dosis orales no se aplica sin una vía exclusivamente oral establecida.
Composición
| Ingrediente medicinal y fuente | Por unidad posológica, según la fuente |
|---|---|
| Acide salicylique Fuente : Synthétique | 27 % |
Ingredientes no medicinales
Hydroxypropylcellulose, Flexible collodion, Alcool, Ethyl lactate, Méthacrylate de poly (méthyle), Polybutylene
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
| Adultes et enfants | minimum : 3 ans | 1 Goutte(s) | 24 heures |
Usos autorizados en Canadá
For the removal of common warts.
Texto original en inglés.
Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Cautions and Warnings : DUOFORTE® is for external use only. DUOFORTE® is not recommended in patients with a known sensitivity or allergy to any of the ingredients. DUOFORTE® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. Avoid exposure to healthy skin. DUOFORTE® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFORTE® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, use is not advised in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. Patients should be advised not to inhale the vapour. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a physician if discomfort persists. Pregnancy and Lactation Pregnancy The safety of DUOFORTE® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFORTE® is not recommended during pregnancy. Lactation Salicylates are excreted in human milk. DUOFORTE® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.
Texto original en inglés.
Contra-Indications : Do not use DUOFORTE® if you have diabetes or poor blood circulation. DO not use DUOFORTE® on open wounds, irritated or reddened skin or any area that is infected. Do not use DUOFORTE® on moles, birthmarks, genital warts, warts on the face or mucous membranes, warts with hair growing from them, red edges, or unusual colour.
Texto original en inglés.
Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: rare (greater than or equal to 1/10000 to less than 1/1000). Post-marketing data Immune system disorders Rare: Application site hypersensitivity including inflammation. Skin and subcutaneous tissue disorders Rare: Application site reaction (including pain, irritation, burning sensation, erythema, and pruritus). Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Interactions DUOFORTE® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFORTE® and other topical medicines on the treated area should be avoided.
Texto original en inglés.
Fuente
Ficha oficial de Health Canada, licencia 01939645
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Texto original en francés.
Texto original en francés.
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).